spec sheet8 rows
Axomadol (EN3324) is an investigational centrally acting analgesic that combines opioid receptor agonism with inhibition of noradrenaline, and to a lesser degree serotonin, reuptake.
- Dual opioid and monoamine-reuptake mechanism aimed at pain relief
- Pharmacodynamics have been characterized in healthy-volunteer studies
- Carries typical opioid-class risks such as sedation and respiratory depression
Overview
Basically a next-generation tramadol concept: opioid plus reuptake-inhibitor pain relief, still stuck in the research stage.
Mechanism
Axomadol acts as a mu-opioid receptor while also inhibiting reuptake of noradrenaline and, to a lesser extent, , a dual mechanism conceptually similar to tramadol. Both the parent compound and its O-demethyl contribute to the overall analgesic and monoaminergic effects, which have been characterized using pupil diameter and experimental pain (nociception) as pharmacodynamic markers in healthy volunteers.
receptor fingerprint
Mu-opioid receptorAgonist
Noradrenaline transporterInhibitor
Safetyrisks and cautions, not medical advice
Population pharmacokinetic/pharmacodynamic modeling in healthy subjects has characterized its dose-effect relationship on pupil constriction and pain response, findings consistent with typical opioid pharmacology. As an investigational compound it lacks a marketed drug's long-term safety record, and opioid-class risks such as sedation and respiratory depression apply given its mechanism.
Subjective profileweighing the evidence above
An investigational tramadol-style analgesic that never reached market, so there is no long-term human safety record behind it, and the opioid-class sedation and respiratory depression still apply. Nothing here to pursue over the marketed drugs in the same space.
Resources
No suppliers are provided for compounds like this. This entry is here for reference.
Research
1 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is Axomadol used for?
It was studied as a pain-relieving drug (analgesic), combining opioid action with reuptake inhibition of noradrenaline and serotonin.
How does Axomadol work?
It activates mu-opioid receptors and also blocks reuptake of noradrenaline (and to a lesser degree serotonin), a dual mechanism meant to boost pain relief.
Is Axomadol well-researched?
Its pharmacokinetics and pharmacodynamics have been studied in healthy volunteers, but it remains investigational with no completed marketing program.
Limitations of the evidence
- Never reached the market, so long-term human safety data are limited
Adverse effects
- Carries typical opioid-class risks such as sedation and respiratory depression